GlassScriptPhysician profile
Edward J Meyer
NPI 1295780542
$9,619.42
in general payments reported to CMS, 2019-2025
48 companies · $1,441 in 2025
The $1,441 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,936 · 2020: $569 · 2021: $857 · 2022: $1,581 · 2023: $1,801 · 2024: $1,434 · 2025: $1,441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,675.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,930.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $893.76 | 2019-2025 | Repatha, Evenity, Tepezza |
| Lilly USA, LLC | $778.14 | 2021-2025 | Jardiance, Mounjaro, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $548.60 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $464.65 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $451.69 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $423.37 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astrazeneca Pharmaceuticals LP | $382.55 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.15 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $252.93 | 2019-2022 | |
| Dexcom, INC. | $199.13 | 2022-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $167.17 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $150.97 | 2023 | Arexvy, Shingrix |
| Abbott Laboratories | $131.65 | 2019-2023 | Gallant |
| Medtronic, INC. | $129.69 | 2021-2025 | Minimed 780g, Minimed 770g |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Meyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.